CN106659767B - 用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂 - Google Patents

用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂 Download PDF

Info

Publication number
CN106659767B
CN106659767B CN201580040646.5A CN201580040646A CN106659767B CN 106659767 B CN106659767 B CN 106659767B CN 201580040646 A CN201580040646 A CN 201580040646A CN 106659767 B CN106659767 B CN 106659767B
Authority
CN
China
Prior art keywords
complement
subject
polymorphism
complement pathway
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580040646.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659767A (zh
Inventor
维恩·H·维斯顿-戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CN106659767A publication Critical patent/CN106659767A/zh
Application granted granted Critical
Publication of CN106659767B publication Critical patent/CN106659767B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580040646.5A 2014-06-06 2015-06-08 用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂 Active CN106659767B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410116.6 2014-06-06
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (2)

Publication Number Publication Date
CN106659767A CN106659767A (zh) 2017-05-10
CN106659767B true CN106659767B (zh) 2022-08-30

Family

ID=51266841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580040646.5A Active CN106659767B (zh) 2014-06-06 2015-06-08 用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
US20190225678A1 (en) * 2016-06-07 2019-07-25 Novartis Ag Anti-c5 antibody for treating patients with complement c5 polymorphism
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
EP3612206A1 (en) * 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028968A1 (en) * 2005-09-09 2007-03-15 Evolutec Limited Method of treating myasthenia gravis
WO2008029167A1 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating peripheral nerve disorders
WO2008029169A2 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
WO2011083317A1 (en) * 2010-01-08 2011-07-14 Varleigh Immuno Pharmaceuticals Limited Ev576 for use in the treatment of viral infections of the respiratory tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) 2009-04-20 2009-06-03 Natural Environment Res Council Composition
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028968A1 (en) * 2005-09-09 2007-03-15 Evolutec Limited Method of treating myasthenia gravis
WO2008029167A1 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating peripheral nerve disorders
WO2008029169A2 (en) * 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
WO2011083317A1 (en) * 2010-01-08 2011-07-14 Varleigh Immuno Pharmaceuticals Limited Ev576 for use in the treatment of viral infections of the respiratory tract

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"抗流感病毒药物的分类及研究展望";梁剑平;《中兽医医药杂志》;20060410(第2期);第22-24页 *
"流感怎么分类";古意;《养猪》;20090614;第71页 *

Also Published As

Publication number Publication date
RU2016151179A3 (enExample) 2019-01-22
CN106659767A (zh) 2017-05-10
AU2015270396B2 (en) 2020-07-16
KR20170016893A (ko) 2017-02-14
GB201410116D0 (en) 2014-07-23
RU2700932C2 (ru) 2019-09-24
US11052129B2 (en) 2021-07-06
NZ727053A (en) 2023-10-27
CA2951175A1 (en) 2015-12-10
ES2906632T3 (es) 2022-04-19
MX2016016139A (es) 2017-07-28
IL249237B (en) 2020-09-30
JP2018516944A (ja) 2018-06-28
IL249237A0 (en) 2017-02-28
MX382757B (es) 2025-03-13
US20170196936A1 (en) 2017-07-13
EP3151851B1 (en) 2021-12-01
DK3302519T3 (da) 2022-02-28
RU2016151179A (ru) 2018-07-16
AU2015270396A1 (en) 2016-12-15
PL3302519T3 (pl) 2022-04-25
BR112016028446A2 (pt) 2017-10-24
WO2015185760A1 (en) 2015-12-10
DK3151851T3 (da) 2022-02-28
JP6767396B2 (ja) 2020-10-14
JP7045133B2 (ja) 2022-03-31
EP3151851A1 (en) 2017-04-12
US20180193417A1 (en) 2018-07-12
PL3151851T3 (pl) 2022-04-04
KR102439717B1 (ko) 2022-09-02
JP2017518316A (ja) 2017-07-06
US20210283221A1 (en) 2021-09-16
ES2906630T3 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
CN106659767B (zh) 用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂
JP5557528B2 (ja) 末梢性神経障害の治療方法
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
JP5784078B2 (ja) 呼吸器疾患の治療方法
JP5254792B2 (ja) 重症筋無力症の治療方法
EP3302519B1 (en) Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant